Pre-IPO Growth Companies Fund — Fintech, Biotech & Enterprise Software

Investment Overview

This venture capital fund invests in pre-IPO growth companies at the late-venture and pre-IPO stage across three high-growth sectors: financial technology (fintech), biotechnology and life sciences, and enterprise software. The fund targets a portfolio of at least 15 companies and a capital return of 3–5x over its seven-year life — equivalent to an IRR of approximately 17–25% per annum.

Pre-IPO investing has historically been one of the highest-returning investment strategies available, but access has been almost exclusively limited to large institutional investors — pension funds, university endowments, sovereign wealth funds, and the most established family offices. This fund is structured to provide access to this opportunity class for sophisticated private investors with a USD 250,000 minimum commitment.

Registration of interest is now open. The fund is expected to close to new investors within 90 days of launch. Priority allocation is available for early registrants.

The Pre-IPO Investment Opportunity

When private companies raise late-stage venture capital rounds (Series B, C, D, or specifically pre-IPO rounds), they are typically 12–36 months from a potential public listing or acquisition by a larger company. Investors at this stage are buying into companies that have:

• Demonstrated product-market fit with significant and growing revenue
• A management team with institutional credibility (often includes ex-founders with previous IPO experience)
• A defined path to liquidity — IPO preparation underway, investment bankers engaged, or a pipeline of acquisition interest from strategic buyers
• Valuations that, while no longer at seed prices, are typically at a meaningful discount to the public market multiples that comparable listed companies trade at

The "IPO pop" — the gain from pre-IPO price to first-day trading price — has historically been the source of significant returns for pre-IPO investors. Companies that successfully list often do so at significant premiums to their last private round valuation. While not all companies achieve this outcome (some experience delayed IPOs, price IPOs below their last private round, or remain private indefinitely), a well-constructed portfolio of 15+ companies captures this distribution of outcomes across a diversified set of bets.

Sector Focus

Financial Technology (30–40% allocation): The fintech sector encompasses payments, lending, insurance technology (insurtech), wealth management technology, and financial infrastructure. Despite a significant valuation correction in fintech from 2022–2023 peaks, the fundamental disruption of financial services by technology continues at pace. The fund manager focuses on companies in payments infrastructure, embedded finance, and B2B fintech — segments where enterprise adoption provides more predictable revenue than direct-to-consumer fintech models.

Biotechnology and Life Sciences (30–40% allocation): Biotech pre-IPO investing is a distinct skill set requiring deep scientific and regulatory expertise. The fund manager works with a specialist biotech advisory board that evaluates clinical pipeline, regulatory pathway, competitive landscape, and management capability. The fund focuses on companies with at least one clinical-stage asset that has achieved Phase II proof-of-concept data — reducing binary clinical risk compared with earlier-stage biotech. Therapeutic focus areas include oncology, rare diseases, and GLP-1/metabolic disease.

Enterprise Software (20–30% allocation): Enterprise software companies — selling software subscriptions to businesses rather than consumers — exhibit the most predictable revenue profiles in the pre-IPO universe: high gross margins, recurring annual contracts, strong net revenue retention (existing customers expanding their spend year-over-year), and network effects in platforms. The fund targets companies in AI-enabled enterprise software, security and compliance, and vertical SaaS (software designed for specific industries).

Portfolio Construction and Risk Management

A minimum of 15 companies per portfolio is the fund's structural requirement. Venture capital and pre-IPO returns follow a power-law distribution — a small number of portfolio companies generate the majority of returns, while a larger number either return capital at modest multiples or fail. A portfolio of 15+ companies is the minimum diversification needed to reliably capture the return distribution of the asset class.

The fund does not concentrate more than 15% of committed capital in any single company at the time of initial investment. Reserves are maintained for follow-on investment into the highest-performing portfolio companies (pro-rata rights in subsequent funding rounds).

Expected Outcomes

In a well-diversified pre-IPO portfolio, the fund manager models the following approximate distribution of outcomes:

• 2–3 companies generate 5–10x returns (the "home runs")
• 4–6 companies generate 2–4x returns (strong performers, IPO or strategic exit)
• 5–8 companies return 0.5–2x (modest gains or capital return)
• 2–3 companies are written off (company fails or returns minimal capital)

The 3–5x target return at fund level aggregates this distribution — high individual winners offset the write-offs, with the total portfolio return driven by the home-run outcomes. This is the fundamental arithmetic of venture capital: the strategy only works with sufficient diversification to ensure at least one or two home-run outcomes.

Fund Timeline

The fund operates on a typical venture capital timeline:

• Years 1–2: Capital deployment into 15–20 companies (the investment period)
• Years 3–5: Portfolio monitoring, follow-on investments, and first exits begin
• Years 6–7: Active exit management — IPOs, secondary sales, strategic acquisitions — and final distributions to investors

Capital is called from investors in tranches as deployment opportunities arise during the investment period — investors commit USD 250,000 at signing but fund 30% on closing, with the remainder called over the following 18–24 months.

Risk Factors — Read Carefully

High failure rate: Pre-IPO and venture capital investing involves a high rate of individual company failures. Investors should assume that 15–25% of portfolio companies may return minimal or no capital. This is structurally expected and does not indicate poor fund management — it is the nature of the asset class.

Illiquidity: Capital is locked up for 7 years. There is no meaningful secondary market for fund interests. Investors cannot access their capital during the fund's life and should treat this as completely illiquid. Seven-year lock-ups are standard in venture capital — do not invest capital you may need access to.

IPO and exit uncertainty: Returns depend on successful exits — IPOs, acquisitions, or secondary sales. If public markets remain closed to technology and biotech IPOs for an extended period (as occurred 2022–2023), exits may be delayed beyond the fund's seven-year life, requiring a fund extension.

Valuation opacity: Private company valuations are not marked to market daily. The fund's NAV reporting reflects periodic, judgement-based valuations that may not accurately reflect realised exit values.

Biotech clinical risk: Even Phase II-validated drug programmes can fail in Phase III trials. A biotech portfolio company could see its value fall to near zero following negative clinical trial data.

Very high risk overall: This is a speculative investment. While the expected-value return target is 3–5x, individual investors could receive significantly less than their original capital, and in a severe downside scenario could lose the majority of their investment. This fund is only appropriate for investors who can afford to lose their entire investment without material impact on their financial position.

How to Enquire

Contact our investment team to register interest, receive the preliminary information memorandum and partnership agreement, and secure your place on the priority allocation list. This fund is expected to close quickly once launched. Minimum commitment USD 250,000.

Important: Target return of 3–5x is the fund manager's projection based on expected portfolio construction and historical venture capital return distributions. It is not guaranteed and is subject to extreme variance. Venture capital and pre-IPO investing is highly speculative and may result in the loss of all invested capital. This fund is only appropriate for sophisticated investors who fully understand and can bear the risks. Independent financial and legal advice is strongly recommended before committing capital.